Navigating Cross‑Border Healthcare Data Transfers: DPDPA vs GDPR

India’s Data Protection Bill (DPDPA) is set to reshape how hospitals, labs and tele‑medicine platforms handle patient information, especially when that data travels beyond India’s borders. The stakes are high: a breach of cross‑border healthcare data not only jeopardises individual privacy but can trigger massive fines under the European Union’s General Data Protection Regulation (GDPR) and invite scrutiny from India’s nascent data‑protection authority. As multinational collaborations in clinical research, AI‑driven diagnostics and health‑tech outsourcing accelerate, organisations must reconcile two very different regulatory regimes. This article dissects the friction points, enforcement challenges and practical steps that Indian entities can take to stay on the right side of both DPDPA and GDPR.

Why Cross‑Border Healthcare Data Transfers Matter

Patient records, genomic sequences and real‑time monitoring feeds are now commodities in a global data market. Cross‑border healthcare data fuels multi‑centre trials, powers predictive algorithms hosted on overseas clouds, and enables remote specialist consultations. The upside is undeniable: faster drug development, more accurate diagnoses and broader access to expertise. Yet the same flows expose individuals to jurisdictional mismatches in privacy standards. A data breach in a European data centre can activate GDPR’s 20 million‑euro fine ceiling, while an Indian regulator may still be defining its enforcement toolkit. The dual exposure creates a compliance quagmire that can cripple reputation and finances.

DPDPA’s Approach to International Data Flow

The DPDPA treats every entity that processes personal data as a “data fiduciary” with a heightened duty of care. For cross‑border transfers, the bill mandates either (i) a determination by the Data Protection Authority (DPA) that the destination country offers “adequate” protection, or (ii) the explicit, informed consent of the data principal. Unlike the GDPR, India has not yet published a list of adequacy‑recognized nations, leaving consent as the default mechanism. The legislation also references “standard contractual clauses” (SCCs) but does not prescribe their form, creating uncertainty for contracts drafted today.

Enforcement remains embryonic. The DPDP Authority is slated to become operational in 2027, and its penalty schedule caps fines at 4 % of global turnover or INR 500 crore, whichever is higher. Critics argue that the lack of clear guidance on adequacy and SCCs will lead to a patchwork of ad‑hoc agreements, increasing litigation risk. Moreover, the bill’s exemption for “critical personal data” – a category that includes health information – is ambiguous, prompting concerns that regulators may interpret it narrowly and still apply the full rigour of cross‑border rules.

GDPR’s Adequacy and Standard Contractual Clauses: The Practical Gap

Under GDPR, transfers are permissible when the European Commission issues an adequacy decision, or when the exporter and importer sign SCCs that have been vetted by EU authorities. The Schrems II judgment (2020) added a layer of scrutiny, requiring supplemental technical and organisational measures when the destination’s legal environment is insufficient. Because India currently lacks an adequacy decision, any Indian health‑tech firm must rely on SCCs and demonstrate that Indian law provides comparable safeguards – a tall order given the DPDPA’s nascent status.

The practical gap surfaces in three ways. First, EU data protection authorities may reject Indian SCCs as inadequate, forcing the use of alternative mechanisms such as Binding Corporate Rules, which are costly to develop. Second, the GDPR’s “right to be forgotten” and data‑subject access rights apply irrespective of where the data resides, meaning Indian processors must build robust mechanisms to honor EU requests. Third, the GDPR imposes mandatory breach notification within 72 hours; the DPDPA’s timeline is less defined, potentially leaving Indian entities unprepared for the rapid response demanded by EU partners.

Bridging the Divide: Compliance Strategies for Indian Healthcare Providers

While legislative alignment may take years, organisations can adopt a risk‑based playbook today.

• Conduct a Data Protection Impact Assessment (DPIA) for every cross‑border health‑data project. Map data flows, identify EU‑resident data subjects, and evaluate whether existing safeguards meet GDPR’s “essential equivalence” test.
• Secure explicit, granular consent from patients for each intended international use, clearly stating the destination, purpose and retention period. Store consent records in a tamper‑evident ledger.
• Adopt EU‑style contractual clauses – use the latest European Commission SCC templates and supplement them with technical measures such as end‑to‑end encryption, pseudonymisation and strict access controls.
• Consider data localisation where feasible. Processing sensitive health data on Indian servers and transmitting only anonymised aggregates can sidestep many GDPR transfer hurdles.
• Establish joint‑controller or controller‑processor agreements that allocate responsibilities for data‑subject rights, breach notifications and audit rights. Clear allocation reduces regulator‑imposed liability.
• Monitor regulatory guidance. Both the DPDP Authority and European Data Protection Boards are expected to issue sector‑specific advisories in 2025‑26; staying abreast can prevent surprise enforcement actions.
• Invest in breach‑response capability. Build a 24/7 incident response team that can meet the GDPR’s 72‑hour notification window and the DPDPA’s emerging reporting requirements.

By embedding these controls into corporate governance, Indian healthcare providers not only mitigate the risk of dual fines but also build trust with patients and international partners – a competitive advantage in a data‑driven health ecosystem.

In the coming months, lawmakers in New Delhi and Brussels will likely negotiate “privacy bridges” that could harmonise standards or at least recognise each other’s safeguards. Until such accords materialise, the onus remains on data fiduciaries to treat cross‑border healthcare data as a high‑value asset that demands the strongest possible protection under both regimes. Proactive compliance is no longer optional; it is the price of participating in the global health‑innovation market.

Frequently Asked Questions

What is meant by "cross‑border healthcare data"?

It refers to any personal health information that is transferred from one country to another, such as patient records sent to overseas research labs or cloud servers.

How does the DPDPA differ from GDPR when transferring patient data abroad?

DPDPA relies on explicit consent or a future adequacy decision, while GDPR allows transfers based on EU‑approved adequacy decisions or standard contractual clauses that must meet EU‑level safeguards.

What immediate steps should an Indian hospital take to comply with both regimes?

Start with a DPIA, obtain granular patient consent for each overseas use, adopt EU‑style SCCs, encrypt data in transit, and draft clear joint‑controller agreements.

What are the penalties for non‑compliance under DPDPA and GDPR?

DPDPA can fine up to 4 % of global turnover or INR 500 crore, whichever is higher; GDPR can impose up to €20 million or 4 % of worldwide annual turnover, whichever is greater.

Can standard contractual clauses approved in the EU be used under DPDPA?

They can be used, but the DPDPA does not yet define their exact form, so Indian entities must supplement them with additional safeguards to satisfy both regulators.

Tags: #DPDPA #GDPR #crossborderdata #healthcareprivacy #dataprotectioncompliance #India #EU